GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cancer Prevention Pharmaceuticals Inc (AMEX:CPP) » Definitions » Operating Margin %

CPP (Cancer Prevention Pharmaceuticals) Operating Margin % : -205.01% (As of Mar. 2016)


View and export this data going back to 2016. Start your Free Trial

What is Cancer Prevention Pharmaceuticals Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Cancer Prevention Pharmaceuticals's Operating Income for the three months ended in Mar. 2016 was $-2.13 Mil. Cancer Prevention Pharmaceuticals's Revenue for the three months ended in Mar. 2016 was $1.04 Mil. Therefore, Cancer Prevention Pharmaceuticals's Operating Margin % for the quarter that ended in Mar. 2016 was -205.01%.

The historical rank and industry rank for Cancer Prevention Pharmaceuticals's Operating Margin % or its related term are showing as below:


CPP's Operating Margin % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 6.89
* Ranked among companies with meaningful Operating Margin % only.

Cancer Prevention Pharmaceuticals's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Cancer Prevention Pharmaceuticals's Operating Income for the three months ended in Mar. 2016 was $-2.13 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2016 was $-3.98 Mil.


Cancer Prevention Pharmaceuticals Operating Margin % Historical Data

The historical data trend for Cancer Prevention Pharmaceuticals's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cancer Prevention Pharmaceuticals Operating Margin % Chart

Cancer Prevention Pharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15
Operating Margin %
-3,060.40 -1,195.05 -105.60

Cancer Prevention Pharmaceuticals Quarterly Data
Dec13 Dec14 Mar15 Sep15 Dec15 Mar16
Operating Margin % Get a 7-Day Free Trial -1,285.95 -1,244.63 - -1,527.27 -205.01

Competitive Comparison of Cancer Prevention Pharmaceuticals's Operating Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Cancer Prevention Pharmaceuticals's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cancer Prevention Pharmaceuticals's Operating Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cancer Prevention Pharmaceuticals's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Cancer Prevention Pharmaceuticals's Operating Margin % falls into.


;
;

Cancer Prevention Pharmaceuticals Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Cancer Prevention Pharmaceuticals's Operating Margin % for the fiscal year that ended in Dec. 2015 is calculated as

Operating Margin %=Operating Income (A: Dec. 2015 ) / Revenue (A: Dec. 2015 )
=-3.923 / 3.715
=-105.60 %

Cancer Prevention Pharmaceuticals's Operating Margin % for the quarter that ended in Mar. 2016 is calculated as

Operating Margin %=Operating Income (Q: Mar. 2016 ) / Revenue (Q: Mar. 2016 )
=-2.128 / 1.038
=-205.01 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cancer Prevention Pharmaceuticals  (AMEX:CPP) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Cancer Prevention Pharmaceuticals Operating Margin % Related Terms

Thank you for viewing the detailed overview of Cancer Prevention Pharmaceuticals's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Cancer Prevention Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
Cancer Prevention Pharmaceuticals Inc is a pharmaceutical company. It was originally incorporated under the laws of the state of Arizona on June 9, 2008, as Cancer Prevention Pharmaceuticals, LLC and on December 22, 2009, Cancer Prevention Pharmaceuticals, Inc. was incorporated in the state of Delaware. The Company currently operates mainly in the development and commercialization of compound CPP-1X, otherwise known as DFMO or eflornithine. It is involved in familial adenomatous polyposis, neuroblastoma and the prevention of recurrence in colon cancer survivors. However, CPP also has therapeutic prevention approaches for prostate cancer, breast cancer, and skin cancers which will be developed together with the National Cancer Institute (as resources become available in the future) and multiple academic partners. Its competitors are Marina Biotech, Inc., SLA Pharma AG, StemSynergy Therapeutics, Inc. and Thetis Pharmaceuticals LLC. The Company holds license to approximately six issued patents in the United States. The Company's activities are subject to risks and uncertainties including failure to obtain required regulatory approvals to market the products, once developed, in the USA or foreign markets.

Cancer Prevention Pharmaceuticals Headlines